State Street
CGON icon

State Street’s CG Oncology CGON Stock Holding History

State Street’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$244M Buy
3,437,590
+790,536
+30% +$51.7M 0.01% 923
2026
Q1 		$179M Sell
2,647,054
-349,641
-12% -$19.8M 0.01% 1001
2025
Q4 		$124M Buy
2,996,695
+950,028
+46% +$39.3M ﹤0.01% 1233
2025
Q3 		$82.4M Sell
2,046,667
-119,086
-5% -$3.46M ﹤0.01% 1444
2025
Q2 		$56.3M Buy
2,165,753
+198,264
+10% +$4.78M ﹤0.01% 1616
2025
Q1 		$48.2M Buy
1,967,489
+43,905
+2% +$1.24M ﹤0.01% 1666
2024
Q4 		$55.2M Buy
1,923,584
+222,931
+13% +$7.63M ﹤0.01% 1667
2024
Q3 		$64.2M Buy
1,700,653
+717,722
+73% +$25.2M ﹤0.01% 1575
2024
Q2 		$31M Buy
982,931
+632,100
+180% +$21.9M ﹤0.01% 1908
2024
Q1 		$15.4M Buy
+350,831
New +$14.3M ﹤0.01% 2326

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street's CGON Position: Q2 2026 in Review

State Street increased its CG Oncology (CGON) stake by 30% in Q2 2026, buying an estimated $51.7M and bringing the position to 3,437,590 shares worth $244M. The position accounts for 0.01% of the portfolio, ranked #923.

State Street first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • State Street held 3,437,590 shares of CG Oncology worth $244M as of Q2 2026.
  • State Street bought 790,536 CG Oncology shares in Q2 2026, an estimated $51.7M.
  • CG Oncology made up 0.01% of State Street's portfolio in Q2 2026, its #923 holding.
  • State Street first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.